398 related articles for article (PubMed ID: 27012911)
1. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.
Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF
BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911
[TBL] [Abstract][Full Text] [Related]
2. Relationship between calcium channel blocker class and mortality in dialysis.
Wetmore JB; Mahnken JD; Phadnis MA; Ellerbeck EF; Shireman TI
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1249-58. PubMed ID: 26371369
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.
Griffith TF; Chua BS; Allen AS; Klassen PS; Reddan DN; Szczech LA
Am J Kidney Dis; 2003 Dec; 42(6):1260-9. PubMed ID: 14655199
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.
Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF; Wetmore JB
Kidney Blood Press Res; 2016; 41(6):873-885. PubMed ID: 27871075
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices.
Shafi T; Sozio SM; Luly J; Bandeen-Roche KJ; St Peter WL; Ephraim PL; McDermott A; Herzog CA; Crews DC; Scialla JJ; Tangri N; Miskulin DC; Michels WM; Jaar BG; Zager PG; Meyer KB; Wu AW; Boulware LE;
Medicine (Baltimore); 2017 Feb; 96(5):e5924. PubMed ID: 28151871
[TBL] [Abstract][Full Text] [Related]
7. β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Zhou H; Sim JJ; Shi J; Shaw SF; Lee MS; Neyer JR; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ
Am J Kidney Dis; 2021 May; 77(5):704-712. PubMed ID: 33010357
[TBL] [Abstract][Full Text] [Related]
8. β-Blockers could improve the 28-day and 3-year survival of patients with end-stage renal disease: a retrospective cohort study.
Dong H; Zhou L; Yang L; Lu H; Cao S; Song H; Fu S
Int Urol Nephrol; 2023 Jun; 55(6):1597-1607. PubMed ID: 36719527
[TBL] [Abstract][Full Text] [Related]
9. Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.
Kitchlu A; Clemens K; Gomes T; Hackam DG; Juurlink DN; Mamdani M; Manno M; Oliver MJ; Quinn RR; Suri RS; Wald R; Yan AT; Garg AX
Nephrol Dial Transplant; 2012 Apr; 27(4):1591-8. PubMed ID: 21873621
[TBL] [Abstract][Full Text] [Related]
10. Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis.
Tanaka M; Yamashita T; Koyama M; Moniwa N; Ohno K; Mitsumata K; Itoh T; Furuhashi M; Ohnishi H; Yoshida H; Tsuchihashi K; Miura T;
Clin Exp Nephrol; 2016 Jun; 20(3):469-78. PubMed ID: 26500097
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive medication exposure and cardiovascular outcomes in hemodialysis patients.
Shireman TI; Phadnis MA; Wetmore JB; Zhou X; Rigler SK; Spertus JA; Ellerbeck EF; Mahnken JD
Am J Nephrol; 2014; 40(2):113-22. PubMed ID: 25139551
[TBL] [Abstract][Full Text] [Related]
12. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.
Sim JJ; Bhandari SK; Shi J; Reynolds K; Calhoun DA; Kalantar-Zadeh K; Jacobsen SJ
Kidney Int; 2015 Sep; 88(3):622-32. PubMed ID: 25945406
[TBL] [Abstract][Full Text] [Related]
13. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
14. Dialysis outcomes of elderly Indigenous and non-Indigenous Australians.
McKercher C; Chan HW; Clayton PA; McDonald S; Jose MD
Nephrology (Carlton); 2014 Oct; 19(10):610-6. PubMed ID: 25066470
[TBL] [Abstract][Full Text] [Related]
15. Patient characteristics and outcomes by GN subtype in ESRD.
O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1170-8. PubMed ID: 26092830
[TBL] [Abstract][Full Text] [Related]
16. Effect of statins on survival in patients undergoing dialysis access for end-stage renal disease.
De Rango P; Parente B; Farchioni L; Cieri E; Fiorucci B; Pelliccia S; Manzone A; Simonte G; Lenti M
Semin Vasc Surg; 2016 Dec; 29(4):198-205. PubMed ID: 28779787
[TBL] [Abstract][Full Text] [Related]
17. Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study.
Choi YJ; Ah YM; Kong J; Choi KH; Kim B; Han N; Yu YM; Oh JM; Shin WG; Lee HY; Lee JY
Cardiovasc Ther; 2016 Aug; 34(4):268-75. PubMed ID: 27214564
[TBL] [Abstract][Full Text] [Related]
18. Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: A systematic review and meta-analysis.
Tao S; Huang J; Xiao J; Ke G; Fu P
PLoS One; 2022; 17(12):e0279171. PubMed ID: 36534654
[TBL] [Abstract][Full Text] [Related]
19. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
[TBL] [Abstract][Full Text] [Related]
20. Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients.
Wetmore JB; Mahnken JD; Mukhopadhyay P; Hou Q; Ellerbeck EF; Rigler SK; Spertus JA; Shireman TI
Am J Kidney Dis; 2011 Jul; 58(1):73-83. PubMed ID: 21621889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
